Non-invasive CT based multiregional radiomics for predicting pathologic complete response to preoperative neoadjuvant chemoimmunotherapy in non-small cell lung cancer.

Journal: European journal of radiology
Published Date:

Abstract

PURPOSE: This study aims to develop and validate a multiregional radiomics model to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC), and further evaluate the performance of the model in different specific subgroups (N2 stage and anti-PD-1/PD-L1).

Authors

  • Shuxuan Fan
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China.
  • Jiping Xie
    Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Sunyi Zheng
  • Jing Wang
    Endoscopy Center, Peking University Cancer Hospital and Institute, Beijing, China.
  • Bin Zhang
    Department of Psychiatry, Sleep Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zhanshuo Zhang
    Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Department of Lung Cancer, Lung Cancer Center, Tianjin, China.
  • Shuo Wang
    College of Tea & Food Science, Anhui Agricultural University, Hefei, China.
  • Yuechen Cui
    Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Department of Lung Cancer, Lung Cancer Center, Tianjin, China.
  • Jiaxin Liu
    Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian 361000, People's Republic of China.
  • Xinru Zheng
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin, China.
  • Zhaoxiang Ye
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China. Electronic address: yezhaoxiang@163.com.
  • Xiaonan Cui
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China.
  • Dongsheng Yue
    Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Department of Lung Cancer, Lung Cancer Center, Tianjin, China. Electronic address: yuedongsheng_cg@163.com.